IMBdx (XKRX:461030) Total Assets : ₩40,887 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is IMBdx Total Assets?

IMBdx's Total Assets for the quarter that ended in Mar. 2024 was ₩40,887 Mil.

Total Assets is connected with ROA %. IMBdx's annualized ROA % for the quarter that ended in Mar. 2024 was -46.70%. Total Assets is also linked to Revenue through Asset Turnover. IMBdx's Asset Turnover for the quarter that ended in Mar. 2024 was 0.04.

IMBdx Total Assets Historical Data

The historical data trend for IMBdx's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IMBdx Total Assets Chart

IMBdx Annual Data

Trend

Dec21

Dec22

Dec23

Total Assets

24,033.03

17,350.22

9,820.76

IMBdx Quarterly Data
	Dec21	Dec22	Mar23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial			17,350.22	-	11,702.68	9,820.76	40,887.07

IMBdx Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

IMBdx's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	8322.586	+	1498.178
	=	9,821

IMBdx's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	37620.16	+	3266.908
	=	40,887

IMBdx (XKRX:461030) Total Assets Explanation

Total Assets is connected with ROA %.

IMBdx's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-11839.288	/	( (9820.764	+	40887.069)	/ 2 )
	=	-11839.288	/	25353.9165
	=	-46.70 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

IMBdx's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	902.053	/	( (9820.764	+	40887.069)	/ 2 )
=	902.053	/	25353.9165
=	0.04

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

IMBdx Total Assets Related Terms

Thank you for viewing the detailed overview of IMBdx's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

IMBdx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IMBdx Inc (XKRX:461030) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

131 Gasandigital 1-ro, 21st Floor BYC Highcity Building A, Geumcheon-gu, Seoul, KOR, 08506

Website

https://www.imbdx.com

IMBdx Inc detects and analyzes the genomic profile of tumor DNA with a single draw of blood. It provides personalized and optimized analysis information that can be utilized in therapy selection and monitoring. Its AlphaLiquid platform offers ctDNA-based precision diagnostics solutions across the full continuum of cancer care, from therapy selection (AlphaLiquid 100/HRR) to recurrence and minimal residual disease(MRD) monitoring (CancerDetect), and multi-cancer early detection (CancerFind). Its services are Clinical Service BioPharma, Research, and Healthcare Checkup.

IMBdx Headlines

No Headlines